Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Alteogen (196170 KS): Index Impact of KOSDAQ to KOSPI Transfer

Alteogen (196170 KS): Significant Commercial Success of ALT-B4 Is On Card

Alteogen (196170 KS): More ALT-B4 Licensing Deal to Follow; Fund Raise Wipes Off Uncertainty

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/alteogen-inc" target="_blank" data-smartkarma-citation="entities:15886:1" rel="noopener">Alteogen Inc (196170 KS)</a> has announced two licensing agreements with global pharmaceutical companies for ALT-B4 within the first quarter of this year itself, thereby enhancing the conviction on the platform.</li>
<li>Thus far, Alteogen has signed eight global pharmaceutical licensing agreements for SC formulation conversion. More deals are believed to be lined up for ALT-B4 platform.</li>
<li>The company expects its mid-to-long-term financial stability and growth visibility to be further strengthened as the commercialization of products incorporating the Hybrozyme platform technology accelerates starting in 2026.</li>
</ul>



Alteogen Inc (196170 KS) has announced two licensing agreements with global pharmaceutical companies for ALT-B4 within the first quarter of this year itself, thereby enhancing the conviction on the platform.
Thus far, Alteogen has signed eight global pharmaceutical licensing agreements for SC formulation conversion. More deals are believed to be lined up for ALT-B4 platform.
The company expects its mid-to-long-term financial stability and growth visibility to be further strengthened as the commercialization of products incorporating the Hybrozyme platform technology accelerates starting in 2026.


Alteogen (196170 KS): ALT-B4 Deals Keep on Coming; Number of Commercialized Products to Expand